Key Articles and Guidelines in the Management of Pulmonary Arterial Hypertension: 2011 Update

被引:2
|
作者
Johnson, Samuel G. [1 ]
Kayser, Steven R. [2 ]
Attridge, Rebecca L. [3 ,4 ]
Duvall, Laura [7 ]
Kiser, Tyree H. [6 ]
Moote, Rebecca [8 ]
Reed, Brent N. [5 ]
Rodgers, Jo E. [9 ]
Erstad, Brian [10 ]
机构
[1] Univ Colorado Skaggs Sch Pharm & Pharmaceut S, Clin Pharm Serv, Kaiser Permanente Colorado, Aurora, CO USA
[2] Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA
[3] Univ Texas Hlth Sci Ctr San Antonio, Univ Incarnate Word Feik Sch Pharm, San Antonio, TX 78229 USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA
[5] Univ N Carolina Hlth Care, Chapel Hill, NC USA
[6] Univ Colorado Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO USA
[7] Ohio State Univ Med Ctr, Dept Pharm, Columbus, OH USA
[8] Regis Univ, Dept Pharm Practice, Sch Pharm, Rueckert Hartman Coll Hlth Profess, Denver, CO USA
[9] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA
[10] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
来源
PHARMACOTHERAPY | 2012年 / 32卷 / 06期
关键词
pulmonary arterial hypertension; right heart failure; drug therapy; guidelines;
D O I
10.1002/j.1875-9114.2012.01105.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacotherapeutic approaches for the management of pulmonary arterial hypertension (PAH) have expanded greatly in the last 10 years. Pulmonary arterial hypertension is a relatively rare disease and is associated with myriad disease processes. The older term for PAH, primary PAH, has been changed to represent these differences and to distinguish it from postcapillary PAH associated with left-sided heart failure. Limitations in evaluating treatment approaches for PAH include its rarity, the small number of patients included in clinical trials, and issues regarding the use of placebo-controlled trials in a disease with such a high mortality rate if left untreated. Management options include the use of prostacyclin and prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, as well as traditional background therapy with diuretics, digoxin, calcium channel blockers, and warfarin. Numerous drugs are under investigation to evaluate their possible roles in management. Combination therapy is increasingly becoming a standard approach to therapy, with mounting literature to document effectiveness. Current or emerging roles for the pharmacist in the management of PAH largely involves ensuring access to drug therapy, facilitating specialty pharmacy dispensing, and providing patient counseling. Newer roles may include future drug development, optimized use of investigational drugs, and specialized disease management programs. This compilation includes a series of articles identifying important literature in cardiovascular pharmacotherapy. This bibliography focuses on pharmacotherapeutic management of pulmonary arterial hypertension (PAH). Most of the cited works present the results of significant human clinical studies that have shaped the management of patients with PAH. Limited primary literature is available for some topics, so in addition, consensus documents prepared by expert panels are reviewed. This compilation may serve as a teaching tool, reference resource, or update of the literature for pharmacy clinicians, physicians, and students.
引用
收藏
页码:e134 / e169
页数:36
相关论文
共 50 条
  • [21] Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension
    Idrees, Majdy M.
    Swiston, John
    Nizami, Imran
    Al Dalaan, Abdullah
    Levy, Robert D.
    ANNALS OF THORACIC MEDICINE, 2014, 9 (05) : 79 - 91
  • [22] Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update
    Coons, James C.
    Pogue, Kristen
    Kolodziej, Andrew R.
    Hirsch, Glenn A.
    George, Marjorie Patricia
    CURRENT CARDIOLOGY REPORTS, 2019, 21 (11)
  • [23] Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update
    James C. Coons
    Kristen Pogue
    Andrew R. Kolodziej
    Glenn A. Hirsch
    Marjorie Patricia George
    Current Cardiology Reports, 2019, 21
  • [24] Update on pulmonary arterial hypertension pharmacotherapy
    Velayati, Arash
    Valerio, Marcos G.
    Shen, Michael
    Tariq, Sohaib
    Lanier, Gregg M.
    Aronow, Wilbert S.
    POSTGRADUATE MEDICINE, 2016, 128 (05) : 460 - 473
  • [25] Update on pediatric pulmonary arterial hypertension
    Ivy, Dunbar
    Frank, Benjamin S.
    CURRENT OPINION IN CARDIOLOGY, 2021, 36 (01) : 67 - 79
  • [26] Update on the Treatment of Pulmonary Arterial Hypertension
    Fernandes, Caio J.
    Calderaro, Daniela
    Luppino Assad, Ana Paula
    Salibe-Filho, William
    Kato-Morinaga, Luciana Tamie
    Hoette, Susana
    Piloto, Bruna
    Castro, Marcela Araujo
    Lisboa, Roberta Pontes
    Felix da Silva, Taysa Antonia
    Martins, Murillo de Araujo
    Alves-Jr, Jose L.
    Jardim, Carlos
    Terra-Filho, Mario
    de Souza, Rogerio
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2021, 117 (04) : 750 - 763
  • [27] Pulmonary arterial hypertension and statins: an update
    Katsiki, Niki
    Wierzbicki, Anthony S.
    Mikhailidis, Dimitri P.
    CURRENT OPINION IN CARDIOLOGY, 2011, 26 (04) : 322 - 326
  • [28] Update in pulmonary arterial hypertension 2007
    Humbert, Marc
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (06) : 574 - 579
  • [29] Pulmonary arterial hypertension: Treatment guidelines
    Pitsiou, Georgia G.
    Mitrouska, Ioanna
    PNEUMON, 2012, 25 : 35 - 38
  • [30] Guidelines for the Treatment of Pulmonary Arterial Hypertension
    Vazquez, Zoe G. S.
    Klinger, James R.
    LUNG, 2020, 198 (04) : 581 - 596